Optimizing Y90 Therapy for Radiation Lobectomy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNorthwestern University
About this trial
HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care. The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1.
Eligibility criteria
Qualifiers
AFP >200 and radiological evidence (arterial hypervascularity) of lesion > 2 cm does not require biopsy
Two imaging modalities (triphasic CT, MRI, ultrasound, angiography) demonstrating arterial hypervascularity in the background of cirrhosis does not require biopsy
One imaging modality with a lesion with arterial hypervascularity with wash out in early or delayed venous phase, does not require a biopsy
Child-Pugh stage A
Disqualifiers
Patient must not be pregnant
Has not undergone a hysterectomy or bilateral oophorectomy
Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for > 12 months)
Patients that are claustrophobic and haven't been able to tolerate an MRI in the past. (Patients with mild claustrophobia are eligible and have the option to take
Trial design
Treatments tested in this trial
- Y90 radioembolization
Treatment groups
104 Participants
are divided into 2 treatment groupsSponsors and collaborators
Northwestern University
Lead sponsor
Mayo Clinic
Collaborator
Source ClinicalTrials.gov